吡咯替尼在乳腺癌中的应用及临床进展  

Application and clinical progress of pyrotinib in breast cancer

作　　者：何迈越 刘佳璇 李俏 He Maiyue;Liu Jiaxuan;Li Qiao(Department of Medical Oncology,National Clinical Research Center for Cancer,National Cancer Center,Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京100021

出　　处：《肿瘤研究与临床》2024年第3期229-232,共4页Cancer Research and Clinic

摘　　要：吡咯替尼是一种新型的不可逆的表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER2)双酪氨酸激酶抑制剂,其在HER2阳性乳腺癌患者治疗中展现了卓越的临床效果,其中吡咯替尼与卡培他滨联合治疗晚期乳腺癌在国内外已得到认可。进一步探索是否存在与吡咯替尼联用效果良好的其他抗肿瘤药物、吡咯替尼能否提升早期或中期乳腺癌患者的临床获益等,可开发吡咯替尼的更多潜力。文章对近年吡咯替尼相关研究进展进行综述。Pyrotinib is a new irreversible epidermal growth factor receptor(EGFR)and human epidermal growth factor receptor 2(HER2)dual tyrosine kinase inhibitor,and it has shown excellent clinical efficacy in treatment of HER2-positive breast cancer patients.The combination of pyrotinib and capecitabine in the treatment of advanced breast cancer has been recognized at home and abroad.Further exploration of whether there are other antitumor agents that work well in combination with pyrotinib,and whether pyrotinib can enhance clinical benefit in patients with early-stage or middle-stage breast cancer,could develop additional potential of pyrotinib.This article reviews the progress related to pyrotinib in recent years.

关 键 词：乳腺肿瘤 受体 表皮生长因子 人表皮生长因子受体2 酪氨酸激酶抑制剂 吡咯替尼 

分 类 号：R737.9[医药卫生—肿瘤]